Skip to content

Nicotine Differences in Smokers

Nicotine Discrimination in Smokers

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05159934
Enrollment
11
Registered
2021-12-16
Start date
2022-02-16
Completion date
2023-08-01
Last updated
2023-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nicotine Dependence

Brief summary

The primary aim of this project is to determine the threshold dose of nicotine, which the smokers will be able to differentiate from placebo (saline). Will use IV pulsed-nicotine infusion that closely matches nicotine delivery by inhaled tobacco use (i.e., tobacco cigarette or electronic cigarette), allowing precise and reproducible nicotine delivery. Four nicotine doses (0.1, 0.05, 0.025, and 0.0125 mg nicotine/pulse) which are within the range of nicotine doses that are delivered by cigarettes with very low to regular nicotine content. These doses will be delivered as a cluster of 4 pulsed-nicotine infusions of 2 sec duration with a 28 sec interval between each dose.

Detailed description

Twenty participants will have 2 Experimental Session on 2 separate days. Experimental Session 1 will determine if smokers can reliably discriminate 0.1mg nicotine/pulse nicotine from saline. Experimental Session 2 will determine if smokers can discriminate 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine from saline. Hypothesis: The threshold for discrimination will be 0.05 mg nicotine/pulse and the doses below that (0.025, and 0.0125 mg nicotine/pulse) will be subthreshold. Exploratory Aim: To explore the relationship between the threshold for subjective drug effects and drug discrimination.

Interventions

DRUGSaline

Saline will be use to determine if smokers can discriminate from the nicotine/pulse of nicotine and saline

DRUG0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine

Determine if smokers can discriminate 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine from saline.

Sponsors

Yale University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE (Subject, Investigator)

Masking description

Nicotine dose will be prepared by pharmacy

Intervention model description

Twenty participants will have 2 Experimental Session on 2 separate days. Experimental Session 1 will determine if smokers can reliably discriminate 0.1mg nicotine/pulse nicotine from saline. Experimental Session 2 will determine if smokers can discriminate 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine from saline.

Eligibility

Sex/Gender
ALL
Age
21 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Female and male smokers, aged 18 to 65 years veterans and non-veterans who have been smoking tobacco cigarettes for at least a year * smoke ≥ 5 cigs/day ; * urine cotinine levels \> 100 ng/mL consistent with nicotine intake of an active smoker (23) * not seeking treatment at the time of the study for nicotine dependence * Good health as verified by medical history, screening examination, and screening laboratory tests * For women, not pregnant as determined by pregnancy screening, nor breast feeding, and using acceptable birth control methods.

Exclusion criteria

* History of major medical or psychiatric disorders that the physician investigator deems as contraindicated for the subject to be in the study * regular use of psychotropic medication (antidepressants, antipsychotics, or anxiolytics) * current alcohol or substance dependence for any other recreational or prescription drugs other than nicotine * use of e-cigarettes more than 10 days in the past 30 days * urine drug screening indicating recent illicit drugs use (with the exception of marijuana).

Design outcomes

Primary

MeasureTime frameDescription
Drug Effect Questionnaireover 3 hoursLiking effect

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026